{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:24:01Z","timestamp":1791181441778,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,12,25]],"date-time":"2014-12-25T00:00:00Z","timestamp":1419465600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s12185-014-1724-6","type":"journal-article","created":{"date-parts":[[2014,12,24]],"date-time":"2014-12-24T01:35:33Z","timestamp":1419384933000},"page":"165-172","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A meta-analysis comparing clinical characteristics and outcomes in CALR-mutated and JAK2V617F essential thrombocythaemia"],"prefix":"10.1007","volume":"101","author":[{"given":"Yining","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youwen","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,25]]},"reference":[{"key":"1724_CR1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, et al. Cancer genome project: acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054\u201361.","journal-title":"Lancet"},{"issue":"7037","key":"1724_CR2","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, LeCouedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature. 2005;434(7037):1144\u20138.","journal-title":"Nature"},{"issue":"17","key":"1724_CR3","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779\u201390.","journal-title":"N Engl J Med"},{"issue":"4","key":"1724_CR4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387\u201397.","journal-title":"Cancer Cell"},{"issue":"25","key":"1724_CR5","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379\u201390.","journal-title":"N Engl J Med"},{"issue":"25","key":"1724_CR6","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391\u2013405.","journal-title":"N Engl J Med"},{"key":"1724_CR7","doi-asserted-by":"crossref","unstructured":"McGaffin G, Harper K, Stirling D, et al. JAK2 V617F and CALR mutations are not mutually exclusive findings from retrospective analysis of a small patient cohort. Br J Haematol. 2014 [Epub ahead of print].","DOI":"10.1111\/bjh.12969"},{"issue":"17","key":"1724_CR8","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1002\/cncr.24440","volume":"115","author":"A Tefferi","year":"2009","unstructured":"Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer. 2009;115(17):3842\u20137.","journal-title":"Cancer"},{"key":"1724_CR9","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"1724_CR10","first-page":"719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719\u201348.","journal-title":"J Natl Cancer Inst"},{"key":"1724_CR11","first-page":"690","volume":"58","author":"N Mantel","year":"1963","unstructured":"Mantel N. Chi square tests with one degree of freedom: extensions of the Mantel\u2013Haenszel procedure. J Am Stat Assoc. 1963;58:690\u2013700.","journal-title":"J Am Stat Assoc"},{"key":"1724_CR12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials"},{"key":"1724_CR13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.","journal-title":"Trials."},{"key":"1724_CR14","doi-asserted-by":"crossref","unstructured":"Tefferi A, Wassie EA, Lasho TL, et al. Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia. 2014. [Epub ahead of print].","DOI":"10.1038\/leu.2014.148"},{"key":"1724_CR15","doi-asserted-by":"crossref","unstructured":"Gangat N, Wassie E, Lasho T, et al. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history. Eur J Haematol. 2014. [Epub ahead of print].","DOI":"10.1111\/ejh.12389"},{"issue":"10","key":"1724_CR16","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","volume":"123","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544\u201351.","journal-title":"Blood"},{"issue":"10","key":"1724_CR17","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","volume":"123","author":"G Rotunno","year":"2014","unstructured":"Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014;123(10):1552\u20135.","journal-title":"Blood"},{"issue":"7","key":"1724_CR18","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3324\/haematol.2014.107482","volume":"99","author":"H Andrikovics","year":"2014","unstructured":"Andrikovics H, Krahling T, Balassa K, et al. Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations. Haematologica. 2014;99(7):1184\u201390.","journal-title":"Haematologica"},{"key":"1724_CR19","doi-asserted-by":"crossref","unstructured":"Trifa AP, Popp RA, Cucuianu A, et al. CALR versus JAK2 mutated essential thrombocythaemia\u2014a report on 141 patients. Br J Haematol. 2014. [Epub ahead of print].","DOI":"10.1111\/bjh.13076"},{"key":"1724_CR20","doi-asserted-by":"crossref","unstructured":"Chen CC, Gau JP, Chou HJ, et al. Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia. Ann Hematol. 2014. [Epub ahead of print].","DOI":"10.1007\/s00277-014-2151-8"},{"issue":"9","key":"1724_CR21","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1038\/leu.2014.138","volume":"28","author":"R Fu","year":"2014","unstructured":"Fu R, Xuan M, Zhou Y, et al. Analysis of calreticulin mutations in Chinese patients with essential thrombocythemia: clinical implications in diagnosis, prognosis and treatment. Leukemia. 2014;28(9):1912\u20134.","journal-title":"Leukemia"},{"key":"1724_CR22","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","volume":"118","author":"W Vainchenker","year":"2011","unstructured":"Vainchenker W, Delhommeau F, Constantinescu SN, et al. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;118:1723\u201335.","journal-title":"Blood"},{"key":"1724_CR23","doi-asserted-by":"crossref","unstructured":"Qiao C, Sun C, Ouyang Y,et al. Clinical importance of different calreticulin gene mutation types in wildtype JAK2 essential thrombocythemia and myelofibrosis patients. Haematologica. 2014. [Epub ahead of print].","DOI":"10.3324\/haematol.2014.109199"},{"key":"1724_CR24","doi-asserted-by":"crossref","unstructured":"Shen H, Chao H, Ding Z, et al: CALR and ASXL1 mutation analysis in 190 patients with essential thrombocythemia. Leuk Lymphoma. 2014. [Epub ahead of print].","DOI":"10.3109\/10428194.2014.939963"},{"issue":"22","key":"1724_CR25","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","volume":"117","author":"A Carobbio","year":"2011","unstructured":"Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117(22):5857\u20139.","journal-title":"Blood"},{"issue":"2","key":"1724_CR26","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1056\/NEJMc1401255","volume":"371","author":"B Cassinat","year":"2014","unstructured":"Cassinat B, Verger E, Kiladjian JJ. Interferon alfa therapy in CALR-mutated essential thrombocythemia. N Engl J Med. 2014;371(2):188\u20139.","journal-title":"N Engl J Med"},{"issue":"7","key":"1724_CR27","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/leu.2014.35","volume":"28","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Thiele J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia. 2014;28(7):1407\u201313.","journal-title":"Leukemia"},{"key":"1724_CR28","author":"X Cabagnols","year":"2014","unstructured":"Cabagnols X, Defour JP, Ugo V, et al. Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution. Leukemia. 2014;. doi: 10.1038\/leu.2014.270 .","journal-title":"Leukemia"},{"issue":"8","key":"1724_CR29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ajh.23743","volume":"89","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Wassie EA, Guglielmelli P, et al. Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol. 2014;89(8):121\u20134.","journal-title":"Am J Hematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-014-1724-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-014-1724-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-014-1724-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,18]],"date-time":"2019-08-18T19:58:45Z","timestamp":1566158325000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-014-1724-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,25]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["1724"],"URL":"https:\/\/doi.org\/10.1007\/s12185-014-1724-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,25]]}}}